Panacur Equine Guard with Apple and Cinnamon Flavour 10% w/v Oral Suspension

البلد: المملكة المتحدة

اللغة: الإنجليزية

المصدر: VMD (Veterinary Medicines Directorate)

اشتر الآن

تأكيد الحساب خصائص المنتج (SPC)
07-07-2023

العنصر النشط:

Fenbendazole

متاح من:

MSD Animal Health UK Limited

ATC رمز:

QP52AC13

INN (الاسم الدولي):

Fenbendazole

الشكل الصيدلاني:

Oral suspension

نوع الوصفة الطبية :

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

المجموعة العلاجية:

Horses

المجال العلاجي:

Anthelmintic

الوضع إذن:

Authorized

تاريخ الترخيص:

1998-10-07

خصائص المنتج

                                Revised: December 2020
AN: 01394/2020
Page 1 of 6
SUMMARY OF PRODUCT CHARTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Panacur Equine Guard with Apple and Cinnamon Flavour
10% w/v Oral Suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 225 ml bottle contains:
Active substance(s)
% w/v
Fenbendazole
10.000
Excipients
Sodium Methyl Parahydroxybenzoate
0.200
Sodium Propyl Parahydroxybenzoate
0.020
For full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral Suspension.
A white, aqueous suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and other equines.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of adult and immature roundworms of the
gastro-intestinal tract in horses and other equines.
The product is also effective for the treatment and control of
encysted
mucosal 3rd and 4th stage small strongyle larvae and is also effective
against
encysted inhibited 3rd stage small strogyle larvae in the mucosa.
It is also effective in controlling other immature and mature
roundworms
including large redworm (_Strongylus edentatus _and _Strongylus
vulgaris_) and
migrating large redworm, _Ascarids _(_Parascaris equorum_), _Oxyuris_
and
_Strongyloides_ species and benzimidazole susceptible adult and
immature
small strongyles (Cyathostomes).
Fenbendazole also has an ovicidal effect on nematode eggs.
Revised: December 2020
AN: 01394/2020
Page 2 of 6
4.3
CONTRA-INDICATIONS
None known.
4.4
SPECIAL WARNING FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase
the risk of development of resistance and could ultimately result in
ineffective
therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Under dosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of calibration of the dosing
device (if any)
Suspected clinical cases of resistance to anthelmintics should be
further
investigated using appropriate tes
                                
                                اقرأ الوثيقة كاملة
                                
                            

تنبيهات البحث المتعلقة بهذا المنتج